Compare REE & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REE | INAB |
|---|---|---|
| Founded | 2011 | 2016 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.1M | 15.6M |
| IPO Year | 2021 | 2020 |
| Metric | REE | INAB |
|---|---|---|
| Price | $0.43 | $1.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 78.4K | 66.7K |
| Earning Date | 06-16-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $327.73 | N/A |
| Revenue Next Year | $36,888.82 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.33 | $1.17 |
| 52 Week High | $1.76 | $4.17 |
| Indicator | REE | INAB |
|---|---|---|
| Relative Strength Index (RSI) | 43.46 | 42.63 |
| Support Level | $0.33 | $1.35 |
| Resistance Level | $0.49 | $1.69 |
| Average True Range (ATR) | 0.04 | 0.12 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 56.81 | 18.00 |
REE Automotive Ltd is an automotive technology company focused on building commercial electric vehicles controlled fully by-wire. The company is in early stages of commercialization and develop and produce software-defined vehicle (SDV) technology that manages vehicle operations and features through proprietarily-developed software. The company has geographical preference in Israel, Germany, United States, United Kingdom, and other regions.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.